Enlivex Therapeutics logo

Enlivex Therapeutics

ENLV | NASDAQ
Chart Builder DCF Calculator
$1.12
-$0.07 (-5.88%)
At close: Nov 16, 2026, 4:00 PM ET
$1.29
+$0.17 (+15.18%)
After-hours: Nov 16, 2026, 7:40 PM ET
-5.88%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 14, 2026
26.1
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #897/1021 (Top 88%)

Key Statistics

Market Data

Market Cap $18.85M
1D Range
1.00 1.13
52W Range
1.00 290.40

Valuation (TTM)

PE -
PB 0.00
EV/EBITDA -1.53

Valuation (NTM)

Forward PE N/A
Forward PEG -0.00
Price Target $15.00
Loading financial charts...

Profile

Enlivex Therapeutics Ltd., established in 2005 and based in Nes Ziona, Israel, operates as a clinical-stage biotechnology firm dedicated to macrophage reprogramming immunotherapy. The company is curre...

Sector Healthcare
Industry Biotechnology
Employees 34
IPO Date Jul 31, 2014
Fiscal Year January - December

Latest News

Enlivex Announces Favorable 12-Month Topline Data from Phase I/IIa Allocetra Trial, Demonstrating Durable Treatment Response

15 days ago · globenewswire.com

Enlivex Announces Favorable 12-Month Topline Data from Phase I/IIa Allocetra Trial, Demonstrating Durable Treatment Response
Enlivex Announces Randomization of 135 Patients in Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis

20 days ago · globenewswire.com

Enlivex Announces Randomization of 135 Patients in Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis
Enlivex Announces Receipt of Delisting Notice from Nasdaq; Intends to Appeal

21 days ago · globenewswire.com

Enlivex Announces Receipt of Delisting Notice from Nasdaq; Intends to Appeal
Enlivex Announces 1-for-16 Reverse Share Split to be Effective October 27, 2026

25 days ago · globenewswire.com

Enlivex Announces 1-for-16 Reverse Share Split to be Effective October 27, 2026
Enlivex Announces Cost Reduction Plan to Focus Resources on Phase 2b Trial of Allocetra™ in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis

29 days ago · globenewswire.com

Enlivex Announces Cost Reduction Plan to Focus Resources on Phase 2b Trial of Allocetra™ in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis
Enlivex Announces Termination of Previously-Announced Financing Payable in RAIN Tokens

2 months ago · globenewswire.com

Enlivex Announces Termination of Previously-Announced Financing Payable in RAIN Tokens
Enlivex Ltd. (ENLV) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

3 months ago · zacks.com

Enlivex Ltd. (ENLV) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Enlivex Treasury Portfolio Update: RAIN Trading Volume Reaches $860MM, 622% Month-Over-Month Growth in July vs June

4 months ago · globenewswire.com

Enlivex Treasury Portfolio Update: RAIN Trading Volume Reaches $860MM, 622% Month-Over-Month Growth in July vs June
Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones

4 months ago · globenewswire.com

Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones

Analyst Summary

# of Analysts
2
Consensus
Hold
Price Target
$15.00
Upside
+1239.29%
Buy (1)
Hold (1)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.